Yifeng Pharmacy Chain Future Growth
Future criteria checks 2/6
Yifeng Pharmacy Chain is forecast to grow earnings and revenue by 17.7% and 17.4% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be 19.7% in 3 years.
Key information
17.7%
Earnings growth rate
17.8%
EPS growth rate
Consumer Retailing earnings growth | 33.8% |
Revenue growth rate | 17.4% |
Future return on equity | 19.7% |
Analyst coverage | Good |
Last updated | 30 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 41,330 | 2,696 | 3,663 | 7,034 | 3 |
12/31/2025 | 34,416 | 2,192 | 2,844 | 3,755 | 15 |
12/31/2024 | 27,408 | 1,752 | 3,895 | 4,948 | 7 |
12/31/2023 | 23,000 | 1,435 | 1,724 | 2,289 | 15 |
9/30/2023 | 22,427 | 1,441 | 3,989 | 4,494 | N/A |
6/30/2023 | 21,843 | 1,394 | 3,690 | 4,235 | N/A |
3/31/2023 | 21,004 | 1,330 | 4,037 | 4,561 | N/A |
12/31/2022 | 19,886 | 1,266 | 3,333 | 3,920 | N/A |
9/30/2022 | 17,736 | 1,016 | 2,090 | 2,792 | N/A |
6/30/2022 | 16,730 | 960 | 1,572 | 2,265 | N/A |
3/31/2022 | 15,845 | 919 | 1,400 | 2,203 | N/A |
12/31/2021 | 15,326 | 888 | 1,322 | 2,150 | N/A |
9/30/2021 | 14,646 | 867 | 1,670 | 2,381 | N/A |
6/30/2021 | 14,198 | 847 | 1,710 | 2,434 | N/A |
3/31/2021 | 13,726 | 798 | 1,812 | 2,486 | N/A |
12/31/2020 | 13,145 | 744 | 1,747 | 2,330 | N/A |
9/30/2020 | 12,324 | 698 | 1,490 | 1,994 | N/A |
6/30/2020 | 11,521 | 637 | 914 | 1,404 | N/A |
3/31/2020 | 10,855 | 583 | 743 | 1,203 | N/A |
12/31/2019 | 10,276 | 544 | 504 | 963 | N/A |
9/30/2019 | 9,636 | 526 | 399 | 774 | N/A |
6/30/2019 | 8,968 | 499 | 435 | 768 | N/A |
3/31/2019 | 7,900 | 463 | 344 | 604 | N/A |
12/31/2018 | 6,913 | 416 | 267 | 511 | N/A |
9/30/2018 | 6,054 | 402 | 172 | 394 | N/A |
6/30/2018 | 5,562 | 384 | 146 | 359 | N/A |
3/31/2018 | 5,211 | 345 | 125 | 345 | N/A |
12/31/2017 | 4,807 | 314 | 110 | 317 | N/A |
9/30/2017 | 4,480 | 285 | -14 | 205 | N/A |
6/30/2017 | 4,210 | 267 | N/A | 193 | N/A |
3/31/2017 | 3,978 | 241 | N/A | 161 | N/A |
12/31/2016 | 3,734 | 224 | N/A | 140 | N/A |
9/30/2016 | 3,540 | 210 | N/A | 207 | N/A |
6/30/2016 | 3,305 | 200 | N/A | 195 | N/A |
3/31/2016 | 3,040 | 187 | N/A | 160 | N/A |
12/31/2015 | 2,846 | 176 | N/A | 182 | N/A |
9/30/2015 | 2,615 | 169 | N/A | 229 | N/A |
6/30/2015 | 2,492 | 161 | N/A | 192 | N/A |
3/31/2015 | 2,373 | 150 | N/A | 235 | N/A |
12/31/2014 | 2,230 | 141 | N/A | 212 | N/A |
12/31/2013 | 1,804 | 99 | N/A | 157 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603939's forecast earnings growth (17.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 603939's earnings (17.7% per year) are forecast to grow slower than the CN market (24.4% per year).
High Growth Earnings: 603939's earnings are forecast to grow, but not significantly.
Revenue vs Market: 603939's revenue (17.4% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 603939's revenue (17.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603939's Return on Equity is forecast to be low in 3 years time (19.7%).